University of Cincinnati Cancer Center study sheds light on enzyme’s role in driving lymphoma growth
Peer-Reviewed Publication
Updates every hour. Last Updated: 10-Jul-2025 09:10 ET (10-Jul-2025 13:10 GMT/UTC)
A study led by University of Cincinnati Cancer Center researchers sheds new light on the mechanisms by which a major oncogene promotes and sustains lymphoma development and progression, paving the way for novel targeted therapies.
A team of researchers from MSK and Weill Cornell Medicine is expanding the understanding of how a decades-old treatment for bladder cancer works — an understanding that could help improve the effectiveness of immunotherapies more broadly.
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer.
Now, a team of researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) and is expanding the understanding of how the treatment works — an understanding that could help improve the effectiveness of immunotherapies more broadly.
Scientists at St. Jude Children’s Research Hospital have found that genetics and type of cancer treatment contribute most to a survivor’s risk of a second cancer.